Cancer

News

Novartis considers "pay-for-performance" for CAR-T

Novartis is considering a “pay-for-performance” pricing scheme if its CAR-T therapy gets approved, following trial results published earlier this week.

News

Chicago, IL - 2017 ASCO Annual Meeting - Attendees and poster presenters during Posters Sessions at the American Society of Clinical Oncology (ASCO) Annual Meeting here today, Saturday June 3, 2017. Over 40,000 physicians, researchers, and healthcare professionals from over 100 countries are attending the 53rd Annual Meeting, which is being held at McCormick Place. The ASCO Annual Meeting highlights the latest findings in all major areas of oncology, from basic to clinical and epidemiological studies. Photo by © ASCO/David Eulitt 2017 Technical Questions: todd@medmeetingimages.com; ASCO Contact: photos@asco.org

High cost of cancer drugs takes centre stage at ASCO

The cost of cancer drugs became a major talking point at this year’s ASCO conference, where doctors raised concerns about the “financial toxicity” patients face in paying for very expensive

Partner Content

T-cells attacking cancer cell illustration of microscopic photos

Partner Content

Beyond Immunotherapies

Latest innovations emerging from immunotherapy research

Partner Content

Partner Content

Managing Multi-Arm Studies in an Evolving Immuno-Oncology La...

Collaborate with CROs and sites to help minimize risks

News

Puma gains as Roche breast cancer combo disappoints

ASCO serves up shock as Roche's data disappoints

News

Natural killer cells are a type of lymphocytes which destroy cancer cells and other altered cells releasing cytotoxic granules.

Chinese CAR-T results offer hope of myeloma cure

This year’s ASCO conference has plenty of data from the CAR-T therapy contenders - but little known Chinese biotech Nanjing Biotech looks to have trumped all the established firms.

Novartis considers "pay-for-performance" for CAR-T

High cost of cancer drugs takes centre stage at ASCO

Beyond Immunotherapies

Managing Multi-Arm Studies in an Evolving Immuno-Oncology La...

Puma gains as Roche breast cancer combo disappoints

Chinese CAR-T results offer hope of myeloma cure

On genomics, NGS, and doing much more good than bad, with Ma...

How to meet your physicians where they are online

Cancer

Editor's Picks